Acupuncture vs no treatment
Number of minor adverse events · Adults with overactive bladder (OAB)
1 finding from 1 review
- no estimate extracted1 study · 24 participantsVery low
Findings
What do systematic reviews say?
3,231 questions · 3,354 findings · 394 reviews
No studies found 803 · 23.9%GRADE not reported 267 · 8%Very low 757 · 22.6%Low 859 · 25.6%Moderate 486 · 14.5%High 182 · 5.4%
Anticoagulant vs no treatment
Adverse events (minor bleeding) · people hospitalised with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
- Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Higher‐dose anticoagulants vs lower‐dose anticoagulants
Adverse events (minor bleeding) · people hospitalised with COVID‐19
Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
- Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes onlyRR 3.28 [1.75, 6.14]3 studies · 1196 participantsHigh
NBI + WLC TURBT vs WLC TURBT
Clavien‐Dindo grade ≤ 2 complications8 · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT showed no clear difference in minor adverse event (Clavien‐Dindo grade I and II) compared with WLC TURBT (low certainty).
1 finding from 1 review
- Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder… 2022 · Cochrane Headline outcomes onlyRR 0.88 [0.49, 1.56]4 studies · 1385 participantsLow
Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)
Fibrinogen · People with periodontitis and metabolic syndrome (no CVD; primary prevention)
1 finding from 1 review
- Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes12 monthsbeta coefficient 10.9 [-12.0, 33.8]1 studyVery low
Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy
Change in sputum P aeruginosa density at end of treatment (cfu/g) · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in sputum P aeruginosa density at end of treatment (cfu/g) compared with combination intravenous anti‐pseudomonal antibiotic therapy (moderate certainty).
2 findings from 1 review
- Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 76 participantsModerate
- Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Patching vs active observation
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged less than 11 years
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Prism adaptation test with eye muscle surgery vs eye muscle surgery alone
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Lateral rectus recession and medial rectus plication vs lateral rectus recession and medial rectus resection
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged over 6 years
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Bilateral lateral rectus recession vs lateral rectus recession and medial rectus resection
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 3 to < 11 years
Bilateral lateral rectus recession showed no clear difference in minor adverse events Defined as any adverse event within 8 weeks of… compared with unilateral lateral rectus recession with medial rectus resection (low certainty).
1 finding from 1 review
- RR 7.36 [0.39, 140.65]1 study · 197 participantsLow
Intervention not reported
Case cross‐over ‐ Urabe or Hoshino · children 9 months to 15 years old
The intervention may leads to higher case cross‐over ‐ Urabe or Hoshino (low certainty).
1 finding from 1 review
- Vaccines for measles, mumps, rubella, and varicella in children 2021 · Cochrane Headline outcomes onlyOR 4 [2.23, 7.2]2 studies · 2 participantsLow
Intervention not reported
Cohort study ‐ rhinoconjunctivitis · children 9 months to 15 years old
The intervention showed no clear difference in cohort study ‐ rhinoconjunctivitis (low certainty).
1 finding from 1 review
- Vaccines for measles, mumps, rubella, and varicella in children 2021 · Cochrane Headline outcomes onlyOR 0.64 [0.19, 2.11]1 study · 489 participantsLow
Thrombolytic therapy vs heparin: primary outcome measures
Minor haemorrhagic events (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
- OR 2.97 [1.66, 5.3]13 studies · 1757 participantsLow
Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes onlyRR 3.58 [0.55, 23.44]3 studies · 1440 participantsLow
Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes onlyRR 3.14 [1.85, 5.32]4 studies · 863 participantsModerate
Fondaparinux vs heparin
Minor bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).
1 finding from 1 review
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes onlyRR 1.53 [0.88, 2.66]1 study · 477 participantsModerate
Dalteparin vs tinzaparin
Minor bleeding · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in minor bleeding compared with tinzaparin (low certainty).
1 finding from 1 review
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes onlyRR 0.82 [0.3, 2.21]1 study · 113 participantsLow
Low molecular weight heparin vs unfractionated heparin
Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral hydroxychloroquine vs placebo
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 1.32 [0.24, 7.19]1 study · 47 participantsModerate
Oral dehydroepiandrosterone vs placebo
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 10.5 [3.26, 33.75]1 study · 381 participantsModerate